Lexicon Pharmaceuticals Inc (STU:LX31)
€ 4.096 0 (0%) Market Cap: 400.61 Mil Enterprise Value: 208.24 Mil PE Ratio: 0 PB Ratio: 1.81 GF Score: 51/100

Lexicon Pharmaceuticals Inc at Evercore ISI HealthCONx Conference Transcript

Nov 28, 2023 / 07:35PM GMT
Release Date Price: €4.1
Unidentified Participant

(technical difficulty) Pharmaceuticals. In attendance today are Lonnel Coats, CEO; Jeff Wade, President and CFO; Craig Granowitz, Senior Vice President and CMO; and Tom Garner, SVP and CCO. Gentlemen, welcome. Thanks so much for coming down to Miami for our conference. Love to dig into it. Before we get into specifics, well, to kick it off with you guys maybe spend three to five minutes giving an overview on where Lexicon is going and perhaps maybe highlight some nuances that aren't well appreciated or well noticed by the Street.

Lonnel Coats
Lexicon Pharmaceuticals, Inc - CEO

I'll start if you don't mind. This is Lonnel.

A couple of things, one, is that it's such an awesome opportunity where we are right now. We have INPEFA that has now becoming well received in the marketplace as an important treatment option for heart failure, especially for those patients who are recently discharged or who are had a recent event. And so a very specific area because of a unique label that we have give us an opportunity to address those patients.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot